UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
DC 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of
Report (Date of earliest event reported): December 8,
2010
PHARMATHENE,
INC.
(Exact
name of registrant as specified in its charter)
|
Delaware
|
001-32587
|
20-2726770
|
||
|
(State
or other jurisdiction
of
incorporation)
|
(Commission
File
Number)
|
(IRS
Employer
Identification
No.)
|
|
One Park Place, Suite 450, Annapolis,
Maryland
|
21401
|
|
|
(Address
of principal executive offices)
|
(Zip
Code)
|
Registrant’s
telephone number including area code: (410) 269-2600
(Former
name or former address, if changed since last report)
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
|
¨
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
|
|
¨
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
|
¨
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
|
|
¨
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
|
|
Item
5.02
|
Departure
of Directors or Certain Officers; Election of Directors; Appointment of
Certain Officers; Compensatory Arrangements of Certain
Officers.
|
On December 8, 2010, the Compensation
Committee (the “Committee”) of the Board of Directors of PharmAthene, Inc. (the
“Company”) approved certain compensation for its executive officers, except its
Chief Executive Officer, which included the grant of options to purchase 75,000
shares of its common stock to the Company’s Senior Vice President and Chief
Financial Officer, Charles A. Reinhart III, and Senior Vice President - Quality
and Regulatory Affairs, Wayne Morges.
The stock options were granted pursuant
to the Company’s 2007 Long-Term Compensation Plan, vest over a four year period
in equal annual installments of 25% beginning on December 8, 2011 and are
exercisable for shares of common stock at an exercise price of $3.55, the
closing price of the common stock on the NYSE Amex on the date of
grant. In addition, the Committee approved cash bonuses for Messrs.
Reinhart and Morges consistent with the previously-disclosed terms of the 2010
bonus program.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
PHARMATHENE,
INC.
(Registrant)
|
||
|
Date: December
14, 2010
|
By:
|
/s/ Jordan P. Karp
|
|
Jordan
P. Karp, Esq.
|
||
|
Senior
Vice President and General Counsel
|
||